Skip to main content
Annals of Oncology logoLink to Annals of Oncology
. 2019 Jan 9;30(6):1018. doi: 10.1093/annonc/mdy530

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

W Shi, T Jiang, P Nuciforo, C Hatzis, E Holmes, N Harbeck, C Sotiriou, L Peña, S Loi, D D Rosa, S Chia, A Wardley, T Ueno, J Rossari, H Eidtmann, A Armour, M Piccart-Gebhart, D L Rimm, J Baselga, L Pusztai
PMCID: PMC6594454  PMID: 30624555

Ann Oncol 2017; 28: 128–135 (doi: 10.1093/annonc/mdw434)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB has performed consulting and/or advisory work for Grail, Roche, Lilly, Novartis. He has stock or other ownership interests in Grail.


Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES